Montreal Heart Institute clinical trial pipeline

5 trials changed in the last 30 days: 0 stopped, 5 with notable changes, 0 with minor changes only.

1. Notable

   COME-TAVI · Monitoring Strategy Versus Electrophysiology-guided…COME-TAVI · Monitoring Strategy Versus Electrophysiology-guided Algorithmic Approach With a New LBBB After TAVI

   Primary and study completion pushed from Dec 2026 to Dec 2027

   Montreal Heart Institute·Not applicable· NCT03303612· Registry history of NCT03303612 on ClinicalTrials.gov (opens the registry)

   Updated Oct 14, 2026

2. Notable

   HEART-AI · Harnessing ECG Artificial Intelligence for Rapid…HEART-AI · Harnessing ECG Artificial Intelligence for Rapid Treatment and Accurate Interpretation

   Primary completion pushed from Jan 31, 2026 to Dec 2027

   Also in this update: Primary endpoint(s) modified; Enrollment reduced: 16160 → 5700 participants

   Montreal Heart Institute·Not applicable· NCT06462989· Registry history of NCT06462989 on ClinicalTrials.gov (opens the registry)

   Updated Oct 13, 2026

3. Notable

   HiRO-HCM · Hypertrophic Cardiomyopathy Registry, Biobank and…HiRO-HCM · Hypertrophic Cardiomyopathy Registry, Biobank and Imaging Data Repository

   Primary completion pushed from Feb 23, 2026 to Dec 31, 2030

   Also in this update: Trial status changed: Enrolling by Invitation → Recruiting; Trial sites expanded: 13 → 17 locations

   Montreal Heart Institute·Not specified· NCT05100420· Registry history of NCT05100420 on ClinicalTrials.gov (opens the registry)

   Updated Oct 9, 2026

4. Notable

   DAISEA-ECG · Deployment and Evaluation of Artificial Intelligence…DAISEA-ECG · Deployment and Evaluation of Artificial Intelligence Software for Electrocardiogram Analysis and Management in Primary Care

   Enrolling by invitation only

   Montreal Heart Institute·Not applicable· NCT06637293· Registry history of NCT06637293 on ClinicalTrials.gov (opens the registry)

   Updated Oct 8, 2026

5. Notable

   ASCAD-P · Aspirin in Subclinical Coronary Artery Disease: A Pilot…ASCAD-P · Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial

   Recruitment opened

   Also in this update: Primary completion pushed from May 1, 2027 to Jul 21, 2027; Study completion moved earlier from May 1, 2028 to Jan 2028

   Montreal Heart Institute·Phase 3· NCT07524335· Registry history of NCT07524335 on ClinicalTrials.gov (opens the registry)

   Updated Sep 23, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.